✦ LIBER ✦

PND21 ESTIMATED COSTS OF FINGOLIMOD MONITORING FOR INDIVIDUALS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

✍ Scribed by Trautman, H.; Clark, J.; Huleatt, H.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND30 Cost Analysis of Glatiramer Acetat

✍ Sánchez-de la Rosa, R.; Sabater, E.; Casado, M.A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PND35 Belgian Cost-Utility Analysis of G

✍ S. Drieskens; K. Moeremans 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND33 Cost Minimization Analysis of Fing

✍ B. Verheggen; M. Treur; M. Groot 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND23 Economic Evaluation of Natalizumab

✍ S.T. Alexopoulos; B. Deniz; A.R. Walker; R. Arnold; D. Bates 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

Use of fingolimod in patients with relap

✍ Alroughani, R.; Ahmed, S.F.; Behbehani, R.; Al-Hashel, J. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 295 KB

Cochrane Database of Systematic Reviews

✍ Shaneh Saz, Anas 📂 Article 📅 2011 🏛 John Wiley & Sons, Ltd ⚖ 121 KB